Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alkacitrat is an effervescent pharmaceutical formulation developed by Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., primarily indicated for the symptomatic relief of functional dyspepsia. It consists of a combination of citric acid and sodium citrate, which function as an antacid and alkalizing agent. Upon oral administration, the medication neutralizes excess gastric hydrochloric acid in the stomach, thereby alleviating symptoms such as heartburn, bloating, and epigastric discomfort. Beyond its local gastric effects, the absorbed citrate is metabolized into bicarbonate, which acts as a systemic and urinary alkalizer. This property makes it useful in managing conditions associated with high acidity, such as metabolic acidosis, and in the prevention of certain types of kidney stones by increasing urinary pH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citric acid + sodium citrate (Uni-Pharma).